Holen Sie sich die Stockscreener-App
32.72
2.62%
-0.88
Handel nachbörslich:
32.72
Schlusskurs vom Vortag:
$33.60
Offen:
$33.53
24-Stunden-Volumen:
398.06K
Relative Volume:
0.70
Marktkapitalisierung:
$1.88B
Einnahmen:
$681.88M
Nettoeinkommen (Verlust:
$122.63M
KGV:
15.51
EPS:
2.11
Netto-Cashflow:
$220.18M
1W Leistung:
-2.94%
1M Leistung:
-16.26%
6M Leistung:
-15.91%
1J Leistung:
+9.32%
1-Tages-Spanne:
$32.66
$34.00
1-Wochen-Bereich:
$32.66
$35.10
52-Wochen-Spanne:
$28.14
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Vergleichen Sie HRMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
32.72 | 1.88B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Harmony Biosciences at Leerink Conference: Expanding Horizons in Rare Disorders - Investing.com UK
Earnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Repor - GuruFocus.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc.HRMY - PR Newswire
Proficio Capital Partners LLC Buys New Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences to Present at Upcoming Global Healthcare Conferences - MyChesCo
Harmony Biosciences Holdings, Inc. (HRMY): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - MSN
Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - ACCESS Newswire
Amalgamated Bank Buys 2,074 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Can Harmony Biosciences Reveal New Strategic Plans at Upcoming Miami Healthcare Conferences? - StockTitan
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Principal Financial Group Inc. - Defense World
Equities Analysts Set Expectations for HRMY FY2025 Earnings - Defense World
Harmony Biosciences Reports Record 2024 Revenue, Targets Billion-Dollar Milestone in 2025 - MyChesCo
HRMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money - ACCESS Newswire
Harmony Biosciences Faces Regulatory Setback, Outlines Future Plans for Pitolisant - MSN
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Denali Advisors LLC - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Releases Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
HC Wainwright Cuts Harmony Biosciences (NASDAQ:HRMY) Price Target to $70.00 - MarketBeat
Harmony Biosciences Holdings, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Simply Wall St
Y Intercept Hong Kong Ltd Increases Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
(HRMY) Trading Report - Stock Traders Daily
Harmony Biosciences Holdings Inc to Host Earnings Call - ACCESS Newswire
Harmony Biosciences Earnings Call Highlights Growth and Challenges - TipRanks
Harmony Biosciences (NASDAQ:HRMY) Shares Down 8.2%Here's Why - MarketBeat
Harmony Biosciences Highlights 2025 Catalysts in Sleep/Wake Franchise - Sleep Review
Demystifying Harmony Biosciences Hldgs: Insights From 11 Analyst Reviews - Benzinga
UBS Adjusts Price Target on Harmony Biosciences to $55 From $56, Keeps Buy Rating - Marketscreener.com
Harmony Biosciences stock target cut to $70 at H.C. Wainwright - Investing.com India
Harmony Biosciences stock target cut to $70 at H.C. Wainwright By Investing.com - Investing.com South Africa
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at H.C. Wainwright - StreetInsider.com
Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from Needham & Company LLC - Defense World
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance, Highlights 2025 Catalysts in Sleep, Wake and Fragile X Syndrome Development Programs - Marketscreener.com
Cantor Fitzgerald maintains HRMY stock Overweight rating - Investing.com India
Should Value Investors Buy Harmony Biosciences (HRMY) Stock? - Yahoo Finance
Cantor Fitzgerald Reiterates Overweight Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider.com
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2024 Earnings Call Transcript - Insider Monkey
Cautious Outlook: Sell Rating for Harmony Biosciences Due to Pipeline Concerns and Generic Competition Risks - TipRanks
Harmony Biosciences Exceeds Q4 Expectations with $0.85 EPS and $201.3 Million Revenue - GuruFocus.com
Harmony Biosciences to Announce Q4 & Full Year 2024 Results on February 25, 2025 - MSN
Harmony Biosciences Holdings Inc (HRMY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q4 Earnings and Revenue Estimates - MSN
Harmony Biosciences Reports Strong 2024 Financial Results - TipRanks
FY2025 EPS Estimates for HRMY Lowered by Cantor Fitzgerald - MarketBeat
Harmony Biosciences posts record sales for narcolepsy drug, maps synthetic CBD plans - Green Market Report
Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why - MSN
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Is Harmony Biosciences Holdings, Inc. (HRMY) the Best Small-Cap Growth Stock to Buy Now? - Insider Monkey
Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa
Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):